Background
High-Grade B-cell Lymphoma (HGBL) was a new disease entity proposed in 2016 to define a particularly aggressive subset of DLBCL. It consisted of two entities - HGBL with double hit(DH)/ triple hit(TH) and HGBL,NOS. While the aggressive nature of HGBL with DH/TH is well described, the data on the other subset of HGBL - HGBL,NOS is lacking in literature. We conducted this analysis to study the clinical profile of HGBL,NOS versus DLBCL,NOS.
Methodology
Retrospective, registry-based, single centre analysis of all patients diagnosed between 1.1.2017 till 31.12.2019 with the histopathological diagnosis of (1) DLBCL (2) HGBL,NOS and (3) HGBL with DH/TH.
Results
One hundred and forty four cases were identified, including 109 DLBCL,NOS, 29 HGBL, NOS and 6 cases of HGBL with DH/TH. The comparison of these 3 aggressive lymphoma subsets has been shown in table 1. HGBL,NOS had worse outcome in comparison to DLBCL,NOS (median PFS 20months vs NR, p=0.12) with a median follow up of 19 months. But the multivariate Cox analysis confirmed that DLBCL vs HGBL significantly affected PFS(p<0.005). End of treatment complete remission showed significant(p<0.001) PFS benefit with respect to both subsets. GCB subtype and IPI score significantly(p=0.03) influenced PFS in DLBCL,NOS but not in HGBL NOS. The DA-EPOCH-R arm did significantly (p<0.05) worse than R CHOP arm with respect to DLBCL NOS. For HGBL,NOS the analysis failed to show any significant difference in PFS with respect to different chemotherapeutic regimen delivered (RCHOP/DA EPOCH R/R mini CHOP).
Conclusion
High-grade B-cell lymphoma, NOS is part of the spectrum of aggressive large B -cell lymphomas with prognosis intermediate to DLBCL, NOS and HGBL with DH/TH. The ideal therapeutic regimen for this aggressive lymphoma needs to be addressed prospectively in clinical trials.
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal